FQ Restriction for the Prevention of CDI

CompletedOBSERVATIONAL
Enrollment

5,871

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Clostridium DifficileClostridium Difficile InfectionC Difficile Colitis
Interventions
OTHER

fluoroquinolone preprescription authorization

Requires authorization from Infection Control consult prior to prescribing fluoroquinolone

OTHER

Control

Does not require authorization from Infection Control prior to prescribing fluoroquinolone

Trial Locations (7)

53705

University of Wisconsin Hospital & Clinics, Madison

54601

Gundersen Health Systems, La Crosse

55905

Mayo-Rochester, Rochester

64112

St. Luke's Health System, Kansas City

77555

University of Texas Medical Branch at Galveston, Galveston

85054

Mayo-Arizona, Phoenix

92555

Riverside University Health System Medical Center, Moreno Valley

All Listed Sponsors
collaborator

Agency for Healthcare Research and Quality (AHRQ)

FED

lead

University of Wisconsin, Madison

OTHER

NCT03848689 - FQ Restriction for the Prevention of CDI | Biotech Hunter | Biotech Hunter